Background Medical management of GERD mainly uses proton pump inhibitors. Alginates also have proven efficacy. The aim of this trial was to compare short-term efficacy of an alginate (Gaviscon ...

However, Gaviscon is looking to show how it has all bases covered thanks to its ‘Night Labs’ innovation hub in a fresh tongue-in-cheek campaign. Fatty foods, eating too fast, ...

Gaviscon Advance was launched to provide patients with effective and long lasting relief from heartburn and indigestion. "RB will now review the OFT statement and respond accordingly." Reckitt ...

Gaviscon hit by global shortage due to one key ingredient. A product that many Aussies rely on daily has been hit with a global shortage due to one very specific – and peculiar – reason.

Doctors misdiagnosed a boy with reflux and prescribed Gaviscon - only to realise he actually had a rare bowel condition after he turned green. PM says negotiations continue as Trump says he's ...

Nine years after its patent elapsed, Gaviscon still has 88% of the market for alginic acid compounds in the National Health Service and there is still no generic name. Generic copies of Gaviscon could ...

Reckitt will leverage GrabAds’ retail media network. Health and hygiene brand Reckitt has partnered with GrabAds, the advertising division of Grab, to enhance brand awareness and sales in the ...

Health Secretary Andrew Lansley will lead the way in taking a drug company to court for nearly £90m after allegedly overcharging the NHS for the heartburn treatment Gaviscon.

The supply of Gaviscon to the NHS was looked at by the Office of Fair Trading last year The NHS in England has launched legal action against Reckitt Benckiser, maker of heartburn medicine Gaviscon ...

News; Health; Pregnancy; Pregnant woman's 25p cure for heartburn means she'll 'never use Gaviscon again' She felt "really lucky" with her pregnancy after she went through the first 14 weeks ...

Reckitt Benckiser could be fined up to £700 million for allegedly ripping off the NHS for tens of millions of pounds by rigging the market for its heartburn medicine Gaviscon.

Included patients were randomly allocated to one of two groups: Gaviscon® (4 × 10 mL/day), or omeprazole 20 mg/day. Randomisation by blocks of 3 (2 + 1) was double-blind. Successive blocks were ...